Relmada Therapeutics, Inc. (RLMD)
- Previous Close
0.3983 - Open
0.3900 - Bid 0.2729 x 200
- Ask 0.4745 x 200
- Day's Range
0.3606 - 0.3900 - 52 Week Range
0.2400 - 4.4700 - Volume
359,495 - Avg. Volume
1,757,093 - Market Cap (intraday)
12.052M - Beta (5Y Monthly) 0.18
- PE Ratio (TTM)
-- - EPS (TTM)
-2.6500 - Earnings Date Aug 5, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.87
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
www.relmada.comRecent News: RLMD
View More
Performance Overview: RLMD
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RLMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RLMD
View MoreValuation Measures
Market Cap
13.22M
Enterprise Value
-31.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.37
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-73.14%
Return on Equity (ttm)
-132.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-79.98M
Diluted EPS (ttm)
-2.6500
Balance Sheet and Cash Flow
Total Cash (mrq)
44.91M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-23.85M
Research Analysis: RLMD
View MoreResearch Reports: RLMD
View MoreDaily – Vickers Top Insider Picks for 12/09/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 12/06/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 12/05/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 12/04/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.